- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04563208
Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19 (DuACT)
A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center, randomized, double-blind, 2-arm, parallel-group study of DuACT in participants with clinical symptoms of COVID-19 that have begun within the past 72 hours prior to testing. A confirmatory diagnosis of COVID-19 via nasopharyngeal swab, with a positive PCR result within 48 hours of testing.
Consented participants who complete screening and meet study eligibility criteria will be randomized in a 1:1 ratio to receive DuACT or Placebo for 5 days.
Study drugs will be administered BID for 5 days with a loading dose on Day 1. Following randomization, participants will complete a symptom questionnaire, record temperature and record oxygen saturation daily for 10 days and at day 28. A thermometer and pulse oximeter will be provided to each patient at the baseline visit (Day 1).
On study days 3, 6 and 10 participants will have a clinic or home visit by a home healthcare provider. At these visits, a mid-turbinate nasal swab will be obtained, confirmation of the patient's clinical symptoms questionnaire will be completed and any adverse events will be assessed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa
- Sunnyside Office Park
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed a current EC approved informed consent form
Male or female participants between 18 and 75 years of age, inclusive diagnosis of SARS-CoV-2 infection, with all of the following, with onset of any within the 72 hours prior to testing:
- Presence of fever at time of screening of ≥ 38.0°C (≥ 100.0°F) and/or
- Presence of at least one constitutional symptom associated with Covid-19 (e.g. headache, myalgia, malaise, or fatigue, rash, diarrhea, loss or alteration of taste/smell) of any severity, and/or
- Presence of at least one respiratory symptom (e.g. cough, chest tightness or sore throat) and/or
- Diagnosis of COVID-19 with a positive PCR in the past 48 hours
Exclusion Criteria:
- Pregnant or lactating females
Critically ill with presence of one or more of the following signs:
- difficulty breathing or shortness of breath
- need for admission to a hospital or an intensive care unit,
- acute respiratory failure requiring intubation/mechanical ventilation,
- signs of shock including hypotension
- Oxygen saturation < 92 %
- Any clinically significant screening laboratory results that are greater than 5 times the upper limit of normal.
- Estimated GFR < 50 mL/min/1.73 m2 (calculated using either Modification of Diet in Renal Disease (MDRD) or Cockcroft Gualt
- Known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia
- Hemoglobin less than 10 gm/dL or hematocrit < 30 %
- Retinal eye disease
- Known chronic kidney disease, stage - 5 or receiving dialysis
- Inability to tolerate oral medications
- Allergy or prior adverse reaction to either ribavirin or nitazoxanide
- QTc interval > 450 mSEC for men and women
- History of Torsade de Pointes VT or prior cardiac arrest or congenital long QT interval
- Current treatment with histamine-2 receptor antagonists (H2 blockers) and/or Protein Pump Inhibitors and throughout the study.
- Have been vaccinated against COVID-19
- Have participated in a clinical study in the past 30 days
- Any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that in the investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Arm A: Placebo
Placebo administered
|
Placebo administered on Days 1-5
|
Active Comparator: Arm B: Ribavirin/Nitazoxanide (RBV/NTZ)
Ribavirin/Nitazoxanide (RBV/NTZ) administered
|
Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of decline in viral load
Time Frame: 10 days
|
Rate of decline in viral load over the 10 days after randomization between participants treated with RBV and NTZ for COVID-19 and placebo
|
10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to resolution of viral load
Time Frame: 28 days
|
Time to resolution of viral load, defined by reduction of virus below LLOQ and maintaining it for 2 days.
|
28 days
|
Comparison of proportion of subjects who are asymptomatic and symptomatic
Time Frame: 10 days
|
Comparison of proportion of subjects who are asymptomatic and symptomatic at day 10
|
10 days
|
Rate of decline in viral load
Time Frame: Days 3 and 6
|
To assess the rate of decline in viral load over days 3 and 6 after randomization
|
Days 3 and 6
|
Change in modified NEWS-2
Time Frame: 28 days
|
Assess change in modified National Early Warning System-2 items on a scale of 0 to 20.
HIgher scores meaning greater clinical risk.
|
28 days
|
Proportion of subjects with treatment emergent adverse events
Time Frame: 28 days
|
Proportion of subjects with treatment emergent adverse events leading to study drug discontinuation
|
28 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Simiso Sokhela, Ezintsha
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DUACT-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States